Orum Therapeutics Usa, Inc.
🇺🇸United States
Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene AmplificationHER2 Gene Mutation
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Orum Therapeutics USA, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT05511844
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath